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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of adherence interventions delivered through mobile devices on adherence to treatment for HIV or tuberculosis
(TB), compared with standard of care, non-mobile device adherence interventions, or alternative mobile device interventions.
B A C K G R O U N D
Description of the condition
Tuberculosis (TB) and HIV are infectious diseases that have
broadly overlapping epidemiology and both require prolonged
treatmentwithmultiple drugs. PeoplewithTBare typically treated
for six to 12 months with up to five drugs (WHO 2010), while
people who areHIV-positive require lifelong antiretroviral therapy
(ART) (WHO 2015b). Consequently, many people find it diffi-
cult to maintain adherence throughout treatment, and some peo-
ple undergoing treatment fail to complete treatment programmes
(WHO 2003; Munro 2007b). Interventions to improve adher-
ence and retention in care are therefore important components of
TB and HIV programmes. By improving the effectiveness of an-
timicrobial therapy, they have the potential to improve treatment
outcomes for the individual (Paterson 2000; WHO 2003; Sabin
2015), reduce disease transmission (Eaton 2012), and prevent
the development of drug-resistant organisms (Friedland 1999;
Moonan 2011).
HIV is primarily transmitted from person-to-person via sexual in-
tercourse, although intravenous inoculation (via shared needles in
people who inject drugs or unscreened blood transfusion), and
vertical transmission (from mother to child at birth or via breast-
feeding) are also important modes of transmission (WHO 2014).
The early stages of HIV infection are commonly asymptomatic,
but without treatment the virus causes progressive impairment of
the immune system, and increasing susceptibility to both com-
mon and uncommon infections (WHO 2015d).
The infecting organism that causes TB is Mycobacterium tubercu-
losis, which is primarily transmitted via inhalation of respiratory
droplets. Most infections are initially controlled by the immune
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system but not fully eradicated; an asymptomatic state known as
‘latent TB’. The latent mycobacteria may then become ‘active’ as
a later time, particularly during impaired host immunity such as
that caused by HIV, malnutrition, or diabetes (WHO 2016). The
symptoms and signs of active TB depend on the organs affected,
but the most common site is the lungs which typically presents as
a progressive cough with weight loss and fever.
HIV and TB are major causes of death and continue to exact a
substantial health burden across the globe. In 2014, TB was re-
sponsible for 1.5 million deaths, and HIV for 1.2 million (WHO
2015a). Of the 1.2 million HIV deaths, 0.4 million people who
died were co-infected with TB, and of the 9.6 million people who
were estimated to have developed active TB infection in 2014,
12% were HIV-positive (WHO 2015a). Of the 35 million people
estimated to be infected with HIV globally in 2013, nearly 25mil-
lion were in the World Health Organization (WHO) African re-
gion (WHO 2013). TheWHO African region had 28% of global
TB cases in 2014, and cases in WHO South East Asia and West-
ern Pacific regions collectively accounted for 58% of the global
TB burden (WHO 2015a). Both diseases remain high on the in-
ternational policy agenda; the United Nations (UN) Sustainable
Development Goals (SDGs) call for an end to both epidemics by
2030 (UN 2015).
Description of the intervention
The use of mobile devices to support health care and public health
practice has been labelled ‘Mobile health’ or ‘mHealth’ by the
WHO (WHO2011), and includes any mobile device that utilizes
wireless technology or bluetooth (and is therefore not dependant
on a wired connection). ’eHealth’ is a broader term that covers the
use of any information and communication technology (ICT) for
health and health-related purposes (WHO 2015c).
Within mHealth, devices that are intended to be carried with a
person at all times are particularly suited to adherence interven-
tions, including pagers, mobile phones, smart phones, personal
digital assistants (PDAs), and tablets. These devices support a va-
riety of media: ShortMessaging Services (SMS) or text messaging,
voice or video calls, and specialized software applications (Apps)
(Hamine 2015), which can be used to deliver a range of adherence
interventions (see Table 1). Notably, many of these approaches
are already implemented in TB and HIV control programmes
through more traditional channels, and have been the subject of
previous Cochrane reviews: letter or telephone reminder systems
for improving adherence in TB (Liu 2014); face-to-face directly
observed therapy for treating TB (Karumbi 2015); material incen-
tives and enablers delivered through clinics and community health
workers (Lutge 2015); and patient education and counselling de-
livered via telephone or face-to-face) (M’Imunya 2012). mHealth
interventions therefore offer an alternative or additional approach
to delivery of already complex packages of adherence support.
How the intervention might work
Behavioural theories can be used to understand why patients may
or may not adhere to treatment. Cognitive perspective theories
hold that an ’intention to adhere’ results from a combination of
’personal factors’:
• self-efficacy (a person’s ability to cope with the challenge at
hand); and
• the persons knowledge about the illness, treatment, and
likely outcomes (Munro 2007a).
This intention to adhere may then be facilitated or inhibited by a
variety of other factors (Munro 2007b):
• health system factors (for example, organization of care,
geographical and financial access, side effects);
• structural factors (for example, poverty, gender,
discrimination, law, finances);
• social context factors (for example, family, household, and
community support and attitudes, stigma).
Adherence interventions seek to change behaviour by modifying
these factors, and the ’active components’ of behaviour change in-
terventions have been classified and grouped hierarchically, based
on similar mechanisms of action (Cane 2015):
• Group 1: scheduled consequences, reward and threat;
• Group 2: cues and cue responses;
• Group 3: covert learning and natural consequences;
feedback and monitoring, goals and planning; social support and
social comparison; shaping knowledge, self-belief, and identity
(these subgroups are grouped together because they are
considered to have less distinct mechanisms of action than those
in Groups 1 or 2).
The adherence interventions identified in Table 1 are likely to op-
erate through distinct theoretical mechanisms. They probably all
influence the personal factors affecting adherence, but social sup-
port, monitoring, and incentive/enabler interventionsmay also act
on the social factors, health system factors, and structural factors
respectively (see Figure 1).
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Figure 1. Logic model of factors influencing adherence to medication (adapted from Munro 2007a and
Munro 2007b)
Why it is important to do this review
Mobile technology is already relatively widespread in low- and
high-income countries, where 45% and 79% of the population
had a mobile subscription by the end of 2014, respectively, and
this is expected to grow to 56% and 81% by 2020, with partic-
ularly rapid growth predicted on the African continent (GSMA
2015). The users of social media platforms that deliver mHealth
interventions are of diverse ethnic, racial, and income backgrounds
(Taggart 2015), which increases the accessibility of interventions
delivered in this way. Smart phones, which utilise data connec-
tions to access the internet, are rapidly being taken up in place
of traditional mobile phones, including in developing countries
and on mobile broadband networks, which extends the available
interventions for mHealth adherence interventions (GSMA 2015;
WHO 2015c). The potential value of mHealth approaches to TB
prevention and care has been recognised by the WHO (WHO
2015c).
Despite decades of study, a recent Cochrane review of measures to
improve adherence found there were few, if any, effective interven-
tions with a clinically significant impact (Nieuwlatt 2014), and
underlined that interventions also need to be affordable, and ac-
tionable in real world healthcare settings. mHealth interventions
present an opportunity of an adherence intervention that is both
affordable and actionable at large scale, and are a very active field
of research, with multiple randomized controlled trials (RCTs)
published (particularly for HIV (Mills 2015), or underway (for
TB (WHO 2015c)), hence mHealth adherence intervention ef-
fectiveness needs to be examined by a comprehensive systematic
review.
It may be useful to combine studies in order to increase the power
of our review to examine the effects of an intervention, if there are
enough similarities between the population, type of intervention,
and outcome measured. This review examines adherence in HIV
and TB together for a number of reasons: HIV is a strong risk
factor for TB and consequently they often occur together in the
same person; they share the same or similar high prevalence set-
tings, are relatively more common amongst marginalized groups,
and consequently the health system factors and barriers to care
(and adherence) are likely to be similar; both illnesses require pro-
longed treatment with multiple drugs, even when the patient feels
well; and both illnesses can result in stigmatization of the person
affected, potentially affecting treatment adherence (WHO 2003;
Munro 2007b; Katz 2013). Though condition-related differences
in treatment and support may differentially modify adherence be-
tween participants with TB or HIV, disease- or therapy-specific
factors are not more important determinants of adherence than
other factors such as socioeconomic position and access to health-
care (WHO 2003; Kardas 2013), and similar reservations could
apply when combining different studies within the same target
infection. We will give careful consideration to similarities/dif-
ferences in populations, co-interventions and outcomes measured
when we combine studies for meta-analysis, to best ensure appar-
ent differences in adherence intervention effectiveness are in fact
attributable to the intervention being investigated.
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O B J E C T I V E S
To assess the effects of adherence interventions delivered through
mobile devices on adherence to treatment for HIV or tuberculosis
(TB), compared with standard of care, non-mobile device adher-
ence interventions, or alternative mobile device interventions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Individually randomized controlled trials (RCTs) and cluster-
RCTs.
Types of participants
Adults or children prescribed treatment for HIV, active TB, or
both.
Types of interventions
Intervention
Any intervention that utilizes a participant’s mobile device to pro-
mote adherence to treatment, or adherence to a treatment pro-
gramme. For the purposes of this Cochrane review, mobile device
refers to devices that are intended to be carried on the person (for
example, pager, phone, smart phone, personal digital assistants
(PDA), or tablet). These interventions may be delivered via text
messaging, voice, video, or smart phone applications and may in-
clude any combination of the following components: reminders;
adherence monitoring; social support; financial incentives; cogni-
tive-behavioural, motivational, or educational interventions.
We will exclude interventions that use an automated reminder
device that do not rely on telecommunication, such as ’beepers’.
We will exclude mobile health interventions bundled with other
non-mobile health interventions unless we can analyse the mobile
health intervention outcome data separately. We will only include
interventions delivered using an internet-based platform if the
interventionwas designed and intended for use via amobile device.
Control
Any alternative intervention aimed at increasing adherence, in-
cluding both those delivered through standard (non-mobile de-
vice) approaches and alternative strategies that involve mobile de-
vices. We will also include trials with inactive controls that do not
receive an adherence intervention as part of their usual care.
Types of outcome measures
We will include trials with any measure of adherence to medica-
tion, or a treatment programme (both as a single event e.g. re-
sponse to a single reminder text message to attend an appoint-
ment, or adherence across a treatment programme), but will only
perform quantitative analysis of trials that report certain measures
(formore detail on analysis of specificmeasures of adherence please
see the ’Data extraction and management’ section).
Primary outcomes
We will adopt adherence to medication or adherence to a treat-
ment programme as our primary outcomes, rather than measures
of treatment success. This will extend the potential pooling of tri-
als because it is a shared outcome between TB and HIV partici-
pants, is more commonly measured and reported (particularly in
trials from low- and middle-income countries) and therefore more
easily pooled than biological measures, will have more power to
detect potentially effective interventions than sparsely occurring
endpoints such as death or TB treatment failure, and avoids con-
founding of biological measures of adherence due to co-morbidity,
drug interaction, and drug resistance.
• Measures of adherence to medication:
◦ ’objective’ measures such as pharmacy refill data, pill
count, electronic drug monitoring (EDM), and self-reported
adherence measures such as number or proportion of doses
missed, self-rated estimates of adherence;
• measures of programme adherence:
◦ treatment completion (for TB);
◦ attendance at clinic appointments (either a single
appointment following an intervention, or a series of
appointments, analysed as separate outcomes);
◦ incidence of treatment breaks, where the trial authors
define breaks;
◦ loss to follow-up (participants who withdraw or are
lost to follow-up in each treatment arm).
Secondary outcomes
For treatment of active tuberculosis:
• TB cure;
• TB survival;
• sputum conversion;
• incidence of drug resistance.
For treatment of HIV infection:
• proportion of participants achieving viral load suppression
(at cut-offs defined by the trial authors, but which must be below
the World Health Organization (WHO) suppression criteria of
less than 1000 copies of HIV ribonucleic Acid (RNA) per mL
(Bennett 2008);
• change in CD4 count;
• survival;
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• incidence of drug resistance.
Adverse events
Adverse events of mobile device interventions: unwanted HIV or
TB participant status disclosure; health system factors for failure
to use the mHealth intervention as planned, for example techno-
logical failure or inadequate staff training; and participant factors
for failure to use the mHealth intervention as planned, for exam-
ple due to loss of device, poor network coverage, or language or
literacy barriers.
Search methods for identification of studies
Wewill attempt to identify all potential trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases: Cochrane Infectious Dis-
ease Group (CIDG) Specialized Register; Cochrane Central Reg-
ister of Controlled Trials (CENTRAL), published in theCochrane
Library; MEDLINE (OVID); Embase (OVID); CINAHL (EB-
SCOHost); PsycInfo (EBSCOHost); LILACS (BIREME); Sci-
ence Citation Index Expanded (SCI-EXPANDED, Web of Sci-
ence), Social Sciences citation index (SSCI, Web of Science), and
Conference Proceedings Citation Index- Social Science & Hu-
manities (CPCI-SSH,Web of Science), using the search terms de-
tailed in Appendix 1, which we prepared in collaboration with the
CIDG Information Specialist to offer both a sensitive and specific
search strategy. We will also search the WHO International Clin-
ical Trials Registry Platform (http://www.who.int/ictrp/search/
en/) and ClinicalTrials.gov (https://clinicaltrials.gov/), to identify
ongoing trials, using (tuberculosis OR TB) OR (HIV OR AIDS)
and (“mobile phone” or cell phone or texting or SMS or smart
phone) as search terms.
Searching other resources
We will search for additional trials by reviewing the reference lists
of all included trials and relevant systematic reviews. We will also
contact leading researchers to identify unpublished data.
Data collection and analysis
Selection of studies
Two review authors will each independently screen all the citations
and abstracts of the literature search results to identify potentially
eligible trials using a trial selection form. We will obtain the full-
text reports of potentially eligible trials. We will assess them for
inclusion in the review using a pre-designed eligibility form based
on the inclusion criteria. We will resolve discrepancies through
discussion or, if required, we will consult a third review author.
Where necessary we will contact the trial authors for clarification
of trial methods. We will list the excluded trials and the reasons for
them in a ’Characteristics of excluded studies’ table. Where there
are multiple reports relating to the same trial, we will include all
reports, but we will only extract data from the most up-to-date
report that includes the specified outcome. We will detail the trial
selection process in a PRISMA diagram.
Data extraction and management
We will independently extract data from the included trials us-
ing a piloted, tailored data extraction form. We will resolve any
differences in data extraction through discussion or, if necessary,
by consulting a third review author. After data extraction, we will
enter these data into Review Manager (RevMan) (RevMan 2014).
We will contact the authors of primary trials in case of any doubts
regarding missing data or methodological details of the trial.
From each included trial we will extract information on:
• trial design: start and end dates, trial location (country and
setting), methods of random sequence generation, allocation
concealment, blinding, participant monitoring and follow-up
(self reported adherence, pill count, pharmacy records, or
electronic monitoring), and funding (as stated by the trial
authors);
• participant characteristics: age, gender, treatment regimen,
co-morbidity, average educational attainment, average income if
adults, baseline viral load, baseline adherence, occupation, and
drug use;
• intervention details: mobile device intervention type
(reminder; educational motivation or counselling; social support;
incentive or enabler; mixed), media and device, content and
format of intervention, frequency of intervention, how the
intervention was delivered (for example, automated or by
healthcare professional), period of intervention, fidelity of
intervention delivered (extent to which intervention was
delivered as described), training of staff and participants
required, description of comparator/control arm, and any co-
interventions, use of incentive if not primary intervention and
differential between treatment arms, for example a gift or loan of
a mobile phone as part of a Short Messaging Services (SMS)
intervention, or subsidised medical treatment;
• outcome measurement: outcomes measured and time
points measured, methodologies used (for example, for
measuring medication adherence examples are self-reported, pill
count, pharmacy record, or electronic drug monitoring (EDM)),
if validated measures were used, and duration or assessment
period for the measurement, for example doses missed in the
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previous one week, 30 days, three months.
For dichotomous outcomes we will extract the number of partic-
ipants randomized and analysed in each treatment arm. We will
extract the number of participants that experience the event (nu-
merator) and the total number of participants that start treatment
(denominator).
For continuous outcomes we will extract the mean, the standard
deviation (SD), and the number of people observed. For count
data (for example, incidence of treatment breaks), we will extract
the number of events in the treatment and control group and the
person time at risk in each group, or the rate ratio and a measure
of variance directly from the trial report.
For time-to-event outcomeswewill extract the log hazard ratio and
its standard error, or the hazard ratio with its confidence interval
or P value if the trial only reports these data.
Cluster-RCTs
For cluster-RCTs, we will record the number of clusters, the av-
erage size of clusters, and the method used to adjust for cluster-
ing. If the trial authors adjusted for clustering appropriately, we
will extract the cluster adjusted measure of effect and a measure of
variance. For dichotomous outcomes, if the trial authors did not
adjust for clustering wewill extract the number of participants that
experience the event and the number of participants randomized
to each group. For continuous outcomes, we will extract the sum-
mary effect (mean or median) and the measure of variance (SD or
range).
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each included trial using the Cochrane ’Risk of bias’ assessment
tool (RevMan 2014), and discuss any differences of opinion. In
the case of missing or unclear information, we will contact the
trial authors for clarification.
The Cochrane approach assesses risk of bias across six domains:
sequence generation and allocation concealment (selection bias),
blinding of participants and personnel (performance bias), blind-
ing of outcome assessors (detection bias), incomplete outcome
data (attrition bias), selective outcome reporting (reporting bias),
and other potential biases. For ’other’ biases, we will pay partic-
ular attention to the use of material incentives for participation,
such as phone credit, given to participants dependent on interven-
tion arm. We will also particularly consider if the included trials
used validated instruments to measure outcomes, and, if we do
not quantitatively synthesise trial results in meta-analysis, we will
also consider whether trial authors demonstrated power to detect
a meaningful difference in a measured outcome. For each domain
we will record the methods used by the trial authors to reduce
the risk of bias and assign a judgment of either ’low’, ’high’, or
’unclear’ risk of bias.
For cluster-RCTs, we will also consider baseline imbalance in the
appraisal of selection bias, loss of clusters in the appraisal of attri-
tion bias, and consider the risk of contamination bias (where peo-
ple living in the control areas also benefit from the intervention).
We will summarize the ’Risk of bias’ assessment results using the
’Risk of bias’ summary and the ’Risk of bias’ graph in addition to
the ’Risk of bias’ tables.
Measures of treatment effect
For dichotomous data, we will compare interventions using the
risk ratio. Where trial authors present data as odds ratios, we will
recalculate the effect. Where trial authors present dichotomous
adherence data as the percentage of pills taken with various cut-off
values, to avoid ceiling effects inflating estimates of intervention
effect size, we will favour them in the following order: 95%, 90%,
80%, and 100%.
We will express count data as rate ratios. We will express time-to-
event data as hazard ratios (HRs), and we will assume that the HR
is constant across the follow-up period. For continuous data, we
will compare arithmetic means using mean differences. We will
present all measures with 95% confidence intervals (CIs). We will
report medians and ranges in table format only.
Unit of analysis issues
Where cluster-RCTs have not adjusted their results for the effect
of the cluster design, we will adjust the sample sizes using an esti-
mate of the intra-cluster correlation coefficient (ICC) as described
in Sections 16.3.4 and 16.3.6 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011). Where possible,
we will derive the ICC from the trial itself, or from a similar trial.
If an appropriate ICC is unavailable, we will conduct sensitivity
analyses to investigate the potential effect of clustering by imput-
ing a range of values of ICC.
When a multi-arm trial contributes multiple comparisons to a
particular meta-analysis, we will either combine treatment groups
or split the ’shared’ group as appropriate to avoid double counting.
Dealing with missing data
We will not apply any imputation measures for missing data. We
will attempt to contact trial authors to obtain missing or unclear
data.
Assessment of heterogeneity
Wewill inspect forest plots for overlapping CIs.We will also apply
the Chi² test as a statistical test for the presence of heterogeneity,
with a P value of 0.10 used to indicate statistical significance, and
we will compute the I² statistic to quantify the percentage of the
variability in effect estimates that is due to heterogeneity rather
than sampling error (chance).
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Assessment of reporting biases
Wewill examine the likelihoodof reporting bias using funnel plots,
provided that there is a sufficient number of included trials.
Data synthesis
We will analyse the data using RevMan (Review Manager 2014).
We will conduct the primary analysis in pairwise comparisons
(that is, mobile health interventions versus control/standard of
care, mobile health interventions versus non-mobile health adher-
ence interventions, and head-to-head comparison of alternative
mobile health adherence interventions). When appropriate (that
is, because populations, interventions, and outcome measure and
time points measured are similar enough), we will combine trials
across target infections (that is, participants infected with HIV or
TB). We will also present analyses stratified by the target infec-
tion (HIV, TB, or co-infection with HIV and TB). We will also
substratify by duration of follow-up of outcome measurement by
grouping similar time points together in a single meta-analysis (for
example, adherence in the shorter term up to six months, com-
pared to longer term of over six months).
If an included trial reports several different validated measures of
self-reported adherence, we will preferentially synthesize data from
validated single-item self-rating scale (Likert type) instruments
where responses are transformed to prespecified corresponding
percentage adherence, then quantitative continua such as a visual
analogue scale (VAS), shown to have greatest convergent validity
with more objective measures such as electronic drug monitoring
(EDM), and reduced ceiling effects, respectively (Stirrat 2015);
other self-report instruments have similar convergent validity to
EDM or ceiling effects (Stirrat 2015), so in this case we will select
data collected using validated instruments with themost complete
reporting, or flip a coin to make a random selection. Where mul-
tiple durations of adherence have been used in assessment of self-
reported adherence (for example, adherence over the last seven
days, and over the last 30 days), we will use the measure closest to
30 days because shorter durations may lead to ceiling effects (more
participants self-reporting perfect adherence), and over longer du-
rations recall may be inaccurate (Stirrat 2015).
Where both self-report and objective measures of medication ad-
herence are available, we will use objective measures over self-re-
portedmeasures, in the following order of favour due to increasing
risk of bias (Nieuwlatt 2014): pharmacy record, electronic moni-
toring, pill count, and self-report. For objective measures, we will
use the longest duration of measurement.
We will tabulate results from cluster-RCTs that we cannot adjust
for clustering, and time-to-event data analysed with models other
than a Cox proportional hazards model.
As we expect to find heterogenous participant populations and
interventions, we plan to use a random-effects model for meta-
analysis.
When it is unjustifiable to pool individual trials due to clinical
or statistical heterogeneity, or reporting of an adherence measure
unsuitable for quantitative analysis, we will instead present a nar-
rative synthesis of trial findings.
Quality of the evidence
We will assess the quality of the evidence as it relates to the tri-
als that contribute data to the meta-analyses for the prespecified
outcomes, using the GRADE approach. We will construct ’Sum-
mary of findings’ tables using the GRADEpro Guideline Devel-
opment Tool (GDT) (available from https://gradepro.org/), and
the methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a; Schünemann 2011). We will present
’Summary of findings’ tables for the primary outcomes. We will
justify all decisions to downgrade the quality of the evidence in
the included trials using footnotes and make comments to aid the
reader’s understanding of the review where necessary. We will con-
sider whether there is any additional outcome information that we
were unable to incorporate into the meta-analyses, note this in the
comments, and state if it supports or contradicts the information
from the meta-analyses.
Subgroup analysis and investigation of heterogeneity
Wewill document a variety of factors thatmay influence the effects
of the interventions in the included trials. These will include:
• description of participants in terms of target infection,
gender, age (child or adult), socioeconomic status defined by
educational attainment or income, baseline adherence,
treatment-naive or treatment-experienced at baseline; co-
morbidities that may affect adherence and whose presence was
dependent for participant enrolment for example, substance
addiction, psychiatric disorder, and whether participants are
from key groups ((1) men who have sex with men, (2) people
who inject drugs, (3) people in prisons and closed settings, (4)
sex workers, (5) transgender people, and (6) homeless), average
cost of medical care to participants (where reported), trial
country income (low-, middle-, or high-income as defined by
World Bank criteria), and trial country out-of-pocket health
expenditure (% of total expenditure on health, using World
Bank data);
• description of the intervention, including all the associated
interventions, in terms of:
◦ the mechanism of action based on intervention
behavioural change component (including reminders;
motivational, educational, or counselling; incentive or enabler
mechanism of interventions);
◦ mobile device media used to deliver the intervention
(voice, SMS, video, app, device);
◦ format of intervention (text only, or pictorial/mixed);
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◦ frequency (daily versus less than daily);
◦ personalization of intervention content or schedule.
Where we pool trials by target infection or intervention duration,
wewill explore heterogeneity by subgroup analysis of interventions
with the same mechanism of action (reminder; monitoring; moti-
vational, educational, or counselling; incentive or enabler; mixed),
and at longer duration of follow-up (for example, for 12 months
or longer).
Sensitivity analysis
Wewill conduct sensitivity analyses on the robustness of the results
to the ’Risk of bias’ components.
We will explore the effects of including self-reported measures of
medication adherence.
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A D D I T I O N A L T A B L E S
Table 1. New Table
Table 1. Adherence interventions, mHealth delivery media, factors for non-adherence impacted, and higher-order behavioural
change technique groupings
Adherence intervention mHealth media used to de-
liver intervention
Aherence factor impacted by
intervention
Under-
pinning behavioural change
technique(s) groupings
Reminders to take medication
and attend appointments
SMS; voice; App; device Personal factors Group2: cues and cue responses
Adherence monitor-
ing by health worker (not self-
monitoring)
Two-way SMS; voice; video
DOT; device (treatment moni-
tor box)
Personal factors
Health system factors
Group 1: scheduled conse-
quences, reward and threat
Group 3: feedback and moni-
toring
Social support and peer net-
works
SMS; voice; App (to connect to
social support network)
Personal factors
Social factors
Group 3: social support and so-
cial comparison
Material incentives or enablers
to adhere of attend care
Phone enabled conditional cash
transfer, free phone airtime
Personal factors
Structural factors
Group 1: scheduled conse-
quences; reward and threat
Cognitive-behavioural, motiva-
tional, or educational interven-
tions
SMS; voice; video messaging;
App
Personal factors Group 3: feedback and mon-
itoring, goals and planning;
shaping knowledge, self belief,
and identity
Abbreviations: DOT = directly observed therapy; SMS = short messaging services.
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A P P E N D I C E S
Appendix 1. MEDLINE (OVID) search strategy
1 tuberculosis or TB.mp [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary concept word, unique identifier] .
2 Tuberculosis/dt, pc, th [Drug Therapy, Prevention & Control, Therapy]
4 Antitubercular agents.mp. or Antitubercular Agents/
5 anti-TB or anti-tuberculous or anti-tuberculosis.mp.
6 1 or 2 or 3 or 4 or 5
7 HIV infection.mp. or HIV Infections/
8 exp HIV/
9 human immunodeficiency virus.mp.
10 Acquired Immunodeficiency Syndrome/ or acquired immunodeficiency syndrome or AIDS.mp.
11 (acquired immun* and deficiency syndrome).mp.
12 (HIV* adj2 (people or person* or patient*)).mp.
13 Anti-Retroviral Agents/ or Antiretroviral Therapy, Highly Active/ or antiretroviral.mp. or Anti-HIV Agents/
14 “highly active antiretroviral therapy” OR “HAART”.mp
15 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16 6 or 15
17 medication adherence.mp. or Patient Compliance/ or Medication Adherence/ or Self Care/
18 directly observed therapy.mp. or Directly Observed Therapy/ or DOT*.mp
19 incentives.mp. or Motivation/ or concordance.mp
20 reimbursement.mp. or Reimbursement, Incentive/
21 reminder systems.mp. or Reminder Systems/
22 patient adherence.mp. or Patient Compliance/
23 17 or 18 or 19 or 20 or 21 or 22
24 Telephone/ or Telemedicine/ or Cell Phones/ or mobile phone*.mp.
25 Wireless Technology/ or Text Messaging/ or Computers, Handheld/ or Smartphone/
26 (“cell phone*” or cellphone* or SMS* or MMS or “text message*” or texting or tablet* or “Iphone*” or “social media” or smart
phone* or “multimedia messaging service” or “short messaging service*” or PDA or “mobile device*” or mHealth or telemedicine).mp.
27 24 or 25 or 26
28 16 and 23 and 271
1We will use search terms in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011).
This is the preliminary search strategy for MEDLINE (OVID). We will adapt it for other electronic databases. We will report all search
strategies in full in the final version of the review.
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